This statistical adjustment does not mean the international emergency is over. Instead, it sharpens the picture of a dangerous outbreak caused by a rare strain of the Ebola virus for which there are no approved vaccines or treatments. Here is the latest status of the outbreak based on official data.

The Reason for the Sweeping Revision

The sharp drop in suspected cases reflects a major data cleanup rather than a sudden halt in the epidemic. Early in the outbreak, case counts were inflated because they were based on clinical symptoms alone. Many of the initial suspected cases presented with fever, headache, and muscle aches—symptoms that are nearly indistinguishable from common regional diseases.

As laboratory capacity improved, hundreds of those patients were tested and cleared. The illnesses they were actually suffering from were often fatal but not Ebola; the final diagnoses included malaria, meningitis, and other infections . This confirmed a grim reality on the ground that responders had long suspected: the outbreak was spreading alongside, and masked by, a high background burden of other deadly diseases.

Confirmed Cases and Deaths by Country

The updated figures as of the May 31 revision paint a clearer picture of the epidemic's true scale.

Democratic Republic of the Congo

• 321 confirmed cases
• 48 confirmed deaths
• The epicenter is Ituri province, with 264 confirmed cases, though the outbreak has also spread to North Kivu and South Kivu provinces .

Uganda

• 9 confirmed cases
• 1 confirmed death
• All cases in Uganda have been linked to cross-border importation from the DRC, with no confirmed local transmission chains documented .

Combined, the two countries have reported roughly 330 confirmed cases and 49 confirmed deaths . It is important to note that even these numbers may evolve as investigations into the remaining 116 suspected cases proceed.

A Public Health Emergency Driven by a Rare Strain

The outbreak was officially declared on May 15, 2026, after laboratory tests confirmed the cause: Bundibugyo ebolavirus (BDBV) . Within two days, on May 17, the WHO Director-General declared it a Public Health Emergency of International Concern (PHEIC), the highest level of alarm under global health regulations .

The emergency declaration cited not just the rising case numbers and cross-border spread, but also "significant uncertainties about the true scale of the epidemic." Health officials believe the virus likely spread undetected for several weeks before the first official confirmation. This is because early Ebola symptoms like fever, fatigue, and headaches are notoriously non-specific. In a region with a high burden of malaria, typhoid, and influenza, an outbreak can easily hide in plain sight until a cluster of deaths draws attention .

The Critical Gap: No Approved Medical Countermeasures

This is not the Zaire strain of Ebola, for which licensed vaccines and monoclonal antibody treatments have been stockpiled. The Bundibugyo virus is genetically distinct, and those existing products are ineffective against it. There is no approved vaccine or specific antiviral treatment for Bundibugyo ebolavirus .

• Vaccines: The widely available rVSV-ZEBOV (Ervebo) vaccine works only against the Zaire strain .
• Therapeutics: The antibody treatments Inmazeb and Ebanga are also Zaire-specific .

This leaves health workers with a limited toolkit. The clinical response relies entirely on supportive care: aggressive fluid and electrolyte replacement, pain and fever management, and treatment of any concurrent infections like malaria . Containment and contact tracing are the primary defenses against further spread. The WHO has urgently recommended that two investigational antibody candidates and the antiviral drug obeldesivir be prioritized for use in clinical trials .

Recoveries Reported Without Specific Treatment

Despite this therapeutic gap, there have been signs that good supportive care can save lives. In Bunia, a city in the heart of the Ituri outbreak zone, DRC health authorities reported that at least six Ebola patients have recovered and been discharged. The survivors included nurses and a laboratory technician, individuals who were infected on the front lines of the response . These recoveries underscore the importance of getting patients into treatment centers early, even when a targeted drug is not yet available.

International Response: U.S. Entry Restrictions

The international community has reacted swiftly to try to contain the virus geographically. On May 18, 2026, the U.S. CDC issued a temporary public health order using its Title 42 authority to suspend entry into the United States for nearly all non-U.S. citizens who have been physically present in the DRC, Uganda, or South Sudan within the 21 days prior to arrival .

• Who is banned: Non-U.S. citizens (including non-immigrant visa holders) who have traveled to the three designated countries in the previous 21 days .
• Who can still enter: U.S. citizens, lawful permanent residents, and U.S. nationals are exempt but face strict protocols. They must enter through one of several designated airports, undergo enhanced public health screening, and self-monitor for symptoms for 21 days after leaving the affected region .
• Why South Sudan: The country has no confirmed cases, but its long shared border with Uganda and the broader uncertainty of the epidemic made it a target for preventative measures .

The 30-day order took effect immediately, and the U.S. Department of Homeland Security redirected affected flights to airports such as Washington-Dulles (IAD), Atlanta (ATL), and Houston (IAH) for screening .

This statistical adjustment does not mean the international emergency is over. Instead, it sharpens the picture of a dangerous outbreak caused by a rare strain of the Ebola virus for which there are no approved vaccines or treatments. Here is the latest status of the outbreak based on official data.

The Reason for the Sweeping Revision

The sharp drop in suspected cases reflects a major data cleanup rather than a sudden halt in the epidemic. Early in the outbreak, case counts were inflated because they were based on clinical symptoms alone. Many of the initial suspected cases presented with fever, headache, and muscle aches—symptoms that are nearly indistinguishable from common regional diseases.

As laboratory capacity improved, hundreds of those patients were tested and cleared. The illnesses they were actually suffering from were often fatal but not Ebola; the final diagnoses included malaria, meningitis, and other infections . This confirmed a grim reality on the ground that responders had long suspected: the outbreak was spreading alongside, and masked by, a high background burden of other deadly diseases.

Confirmed Cases and Deaths by Country

The updated figures as of the May 31 revision paint a clearer picture of the epidemic's true scale.

Democratic Republic of the Congo

• 321 confirmed cases
• 48 confirmed deaths
• The epicenter is Ituri province, with 264 confirmed cases, though the outbreak has also spread to North Kivu and South Kivu provinces .

Uganda

• 9 confirmed cases
• 1 confirmed death
• All cases in Uganda have been linked to cross-border importation from the DRC, with no confirmed local transmission chains documented .

Combined, the two countries have reported roughly 330 confirmed cases and 49 confirmed deaths . It is important to note that even these numbers may evolve as investigations into the remaining 116 suspected cases proceed.

A Public Health Emergency Driven by a Rare Strain

The outbreak was officially declared on May 15, 2026, after laboratory tests confirmed the cause: Bundibugyo ebolavirus (BDBV) . Within two days, on May 17, the WHO Director-General declared it a Public Health Emergency of International Concern (PHEIC), the highest level of alarm under global health regulations .

The emergency declaration cited not just the rising case numbers and cross-border spread, but also "significant uncertainties about the true scale of the epidemic." Health officials believe the virus likely spread undetected for several weeks before the first official confirmation. This is because early Ebola symptoms like fever, fatigue, and headaches are notoriously non-specific. In a region with a high burden of malaria, typhoid, and influenza, an outbreak can easily hide in plain sight until a cluster of deaths draws attention .

The Critical Gap: No Approved Medical Countermeasures

This is not the Zaire strain of Ebola, for which licensed vaccines and monoclonal antibody treatments have been stockpiled. The Bundibugyo virus is genetically distinct, and those existing products are ineffective against it. There is no approved vaccine or specific antiviral treatment for Bundibugyo ebolavirus .

• Vaccines: The widely available rVSV-ZEBOV (Ervebo) vaccine works only against the Zaire strain .
• Therapeutics: The antibody treatments Inmazeb and Ebanga are also Zaire-specific .

This leaves health workers with a limited toolkit. The clinical response relies entirely on supportive care: aggressive fluid and electrolyte replacement, pain and fever management, and treatment of any concurrent infections like malaria . Containment and contact tracing are the primary defenses against further spread. The WHO has urgently recommended that two investigational antibody candidates and the antiviral drug obeldesivir be prioritized for use in clinical trials .

Recoveries Reported Without Specific Treatment

Despite this therapeutic gap, there have been signs that good supportive care can save lives. In Bunia, a city in the heart of the Ituri outbreak zone, DRC health authorities reported that at least six Ebola patients have recovered and been discharged. The survivors included nurses and a laboratory technician, individuals who were infected on the front lines of the response . These recoveries underscore the importance of getting patients into treatment centers early, even when a targeted drug is not yet available.

International Response: U.S. Entry Restrictions

The international community has reacted swiftly to try to contain the virus geographically. On May 18, 2026, the U.S. CDC issued a temporary public health order using its Title 42 authority to suspend entry into the United States for nearly all non-U.S. citizens who have been physically present in the DRC, Uganda, or South Sudan within the 21 days prior to arrival .

• Who is banned: Non-U.S. citizens (including non-immigrant visa holders) who have traveled to the three designated countries in the previous 21 days .
• Who can still enter: U.S. citizens, lawful permanent residents, and U.S. nationals are exempt but face strict protocols. They must enter through one of several designated airports, undergo enhanced public health screening, and self-monitor for symptoms for 21 days after leaving the affected region .
• Why South Sudan: The country has no confirmed cases, but its long shared border with Uganda and the broader uncertainty of the epidemic made it a target for preventative measures .

The 30-day order took effect immediately, and the U.S. Department of Homeland Security redirected affected flights to airports such as Washington-Dulles (IAD), Atlanta (ATL), and Houston (IAH) for screening .